Function and Mechanisms of Autophagy-Lysosomal Pathway in Traumatic Brain Injury

自噬-溶酶体途径在脑外伤中的功能和机制

基本信息

  • 批准号:
    9000184
  • 负责人:
  • 金额:
    $ 33.58万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2015
  • 资助国家:
    美国
  • 起止时间:
    2015-03-01 至 2020-02-29
  • 项目状态:
    已结题

项目摘要

 DESCRIPTION (provided by applicant): A major barrier to development of novel treatments against traumatic brain injury (TBI) is incomplete understanding of the mechanisms of injury and recovery. The overall aim of our research is to determine the molecular mechanisms and contribution of defects in the autophagy-lysosomal pathway to secondary injury after TBI, in order to allow future development of rational therapeutic approaches based on its manipulation. The autophagy-lysosomal pathway is an essential component of intracellular degradation and quality control, and plays a protective function against a variety of conditions including neurodegeneration. However, when lysosomal function is compromised autophagy can also contribute to cell death. Accumulation of autophagosomes has been noted after TBI, but its function and mechanisms remain unknown. Additionally, lysosomal function and the efficiency of lysosome-dependent autophagic degradation (flux), has not been assessed after TBI. Therefore, the purpose of this study is to test the hypothesis that early after TBI dysfunction of the autophagy-lysosomal pathway contributes to neuronal cell death and its restoration can promote long-term recovery. Our project will use autophagy-reporter (GFP-LC3) and autophagy-deficient (Beclin1+/-) transgenic mouse models to determine the function of autophagy-lysosomal pathway after TBI and employ both in vivo and in vitro model systems to determine the mechanisms by which disruption of this pathway affects outcomes after TBI. AIM 1 will determine the mechanisms of lysosomal and autophagy dysfunction after TBI. Complimentary in vivo and in vitro approaches, including pharmacological and genetic modulations, will be combined with novel techniques such as ex vivo autophagy flux analysis to test the hypothesis that autophagy flux is impaired early after TBI, reflecting cytoplasmic phospholipase A2 (cPLA2) mediated lysosomal membrane permeabilization (LMP). AIM 2 will determine the functional consequences of enhancing lysosomal function and autophagy flux after TBI. Chemical modulators of autophagy flux and lysosomal biogenesis, Rapamycin and Torin1, will be used in wild type and autophagy deficient mice to test the hypothesis that restoring function of the autophagy-lysosomal pathway after TBI will result in improved functional outcomes. AIM 3 will determine the influence of autophagy-lysosomal pathway on neuronal cell stress and survival after TBI. Pharmacological and genetic manipulation of autophagy, lysosomal function and ER stress in vivo and in vitro will be used to test the hypothesis that impaired lysosomal activity and autophagic clearance exacerbate ER stress resulting in neuronal apoptosis after TBI. Our study will for the first time determine the functio and the mechanisms of autophagy-lysosomal pathway after TBI. Additionally, we will demonstrate that increasing lysosomal function and autophagy flux can improve histological and behavioral outcomes after TBI, thus opening potential novel treatment avenues.
 DESCRIPTION (provided by applicant): A major barrier to development of novel treatments against traumatic brain injury (TBI) is incomplete understanding of the mechanisms of injury and recovery. The overall aim of our research is to determine the molecular mechanisms and contribution of defects in the autophagy-lysosomal pathway to secondary injury after TBI, in order to allow future development of rational therapeutic approaches based on its manipulation. The autophagy-lysosomal pathway is an essential component of intracellular degradation and quality control, and plays a protective function against a variety of conditions including neurodegeneration. However, when lysosomal function is compromised autophagy can also contribute to cell death. Accumulation of autophagosomes has been noted after TBI, but its function and mechanisms remain unknown. Additionally, lysosomal function and the efficiency of lysosome-dependent autophagic degradation (flux), has not been assessed after TBI. Therefore, the purpose of this study is to test the hypothesis that early after TBI dysfunction of the autophagy-lysosomal pathway contributes to neuronal cell death and its restoration can promote long-term recovery. Our project will use autophagy-reporter (GFP-LC3) and autophagy-deficient (Beclin1+/-) transgenic mouse models to determine the function of autophagy-lysosomal pathway after TBI and employ both in vivo and in vitro model systems to determine the mechanisms by which disruption of this pathway affects outcomes after TBI. AIM 1 will determine the mechanisms of lysosomal and autophagy dysfunction after TBI. Complimentary in vivo and in vitro approaches, including pharmacological and genetic modulations, will be combined with novel techniques such as ex vivo autophagy flux analysis to test the hypothesis that autophagy flux is impaired early after TBI, reflecting cytoplasmic phospholipase A2 (cPLA2) mediated lysosomal membrane permeabilization (LMP). AIM 2 will determine the functional consequences of enhancing lysosomal function and autophagy flux after TBI. Chemical modulators of autophagy flux and lysosomal biogenesis, Rapamycin and Torin1, will be used in wild type and autophagy deficient mice to test the hypothesis that restoring function of the autophagy-lysosomal pathway after TBI will result in improved functional outcomes. AIM 3 will determine the influence of autophagy-lysosomal pathway on neuronal cell stress and survival after TBI. Pharmacological and genetic manipulation of autophagy, lysosomal function and ER stress in vivo and in vitro will be used to test the hypothesis that impaired lysosomal activity and autophagic clearance exacerbate ER stress resulting in neuronal apoptosis after TBI. Our study will for the first time determine the functio and the mechanisms of autophagy-lysosomal pathway after TBI. Additionally, we will demonstrate that increasing lysosomal function and autophagy flux can improve histological and behavioral outcomes after TBI, thus opening potential novel treatment avenues.

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

MARTA M LIPINSKI其他文献

MARTA M LIPINSKI的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('MARTA M LIPINSKI', 18)}}的其他基金

Regulation of LDAM by autopahgy in the aging brain
衰老大脑中自噬对 LDAM 的调节
  • 批准号:
    10900994
  • 财政年份:
    2023
  • 资助金额:
    $ 33.58万
  • 项目类别:
Dysregulation of autophagy-lysosomal function links TBI to late-onset neurodegeneration
自噬-溶酶体功能失调将 TBI 与迟发性神经变性联系起来
  • 批准号:
    10611981
  • 财政年份:
    2020
  • 资助金额:
    $ 33.58万
  • 项目类别:
Dysregulation of autophagy-lysosomal function links TBI to late-onset neurodegeneration
自噬-溶酶体功能失调将 TBI 与迟发性神经变性联系起来
  • 批准号:
    10388269
  • 财政年份:
    2020
  • 资助金额:
    $ 33.58万
  • 项目类别:
The Function and Mechanisms of Autophagy in Spinal Cord Injury
自噬在脊髓损伤中的功能和机制
  • 批准号:
    10439021
  • 财政年份:
    2016
  • 资助金额:
    $ 33.58万
  • 项目类别:
Function and Mechanisms of Autophagy-Lysosomal Pathway in Traumatic Brain Injury
自噬-溶酶体途径在脑外伤中的功能和机制
  • 批准号:
    9207120
  • 财政年份:
    2015
  • 资助金额:
    $ 33.58万
  • 项目类别:
The PARK10 gene USP24 affects Parkinson's Disease via regulation of autophagy
PARK10 基因 USP24 通过调节自噬影响帕金森病
  • 批准号:
    8822475
  • 财政年份:
    2014
  • 资助金额:
    $ 33.58万
  • 项目类别:
The PARK10 gene USP24 affects Parkinson's Disease via regulation of autophagy
PARK10 基因 USP24 通过调节自噬影响帕金森病
  • 批准号:
    8931076
  • 财政年份:
    2014
  • 资助金额:
    $ 33.58万
  • 项目类别:

相似海外基金

A platform for rapidly generating live attenuated enterovirus vaccines
快速生成减毒肠道病毒活疫苗的平台
  • 批准号:
    24K02286
  • 财政年份:
    2024
  • 资助金额:
    $ 33.58万
  • 项目类别:
    Grant-in-Aid for Scientific Research (B)
I-Corps: Translation potential of an efficient method to generate live-attenuated and replication-defective DNA viruses for vaccine development
I-Corps:一种有效方法的转化潜力,可生成用于疫苗开发的减毒活病毒和复制缺陷型 DNA 病毒
  • 批准号:
    2420924
  • 财政年份:
    2024
  • 资助金额:
    $ 33.58万
  • 项目类别:
    Standard Grant
Developing a robust native extracellular matrix to improve islet function with attenuated immunogenicity for transplantation
开发强大的天然细胞外基质,以改善胰岛功能,并减弱移植的免疫原性
  • 批准号:
    10596047
  • 财政年份:
    2023
  • 资助金额:
    $ 33.58万
  • 项目类别:
Live attenuated non-transmissible (LANT) Klebsiella pneumoniae vaccines
肺炎克雷伯氏菌减毒非传染性 (LANT) 活疫苗
  • 批准号:
    10742028
  • 财政年份:
    2023
  • 资助金额:
    $ 33.58万
  • 项目类别:
Protecting Pigs From Enzootic Pneumonia: Rational Design Of Safe Attenuated Vaccines.
保护猪免受地方性肺炎:安全减毒疫苗的合理设计。
  • 批准号:
    BB/X017540/1
  • 财政年份:
    2023
  • 资助金额:
    $ 33.58万
  • 项目类别:
    Research Grant
A “Goldilocks” live attenuated poultry vaccine for Infectious Coryza
用于传染性鼻炎的“Goldilocks”家禽减毒活疫苗
  • 批准号:
    LP210301365
  • 财政年份:
    2023
  • 资助金额:
    $ 33.58万
  • 项目类别:
    Linkage Projects
A novel live-attenuated Zika vaccine with a modified 5'UTR
一种带有改良 5UTR 的新型寨卡减毒活疫苗
  • 批准号:
    10730832
  • 财政年份:
    2023
  • 资助金额:
    $ 33.58万
  • 项目类别:
Combating melanoma with an attenuated bacterial therapeutic
用减毒细菌疗法对抗黑色素瘤
  • 批准号:
    10659841
  • 财政年份:
    2023
  • 资助金额:
    $ 33.58万
  • 项目类别:
L2M NSERC-Bioengineering attenuated Sclerotinia sclerotiorum strains as bioherbicide for cereal production and lawn management
L2M NSERC-生物工程减毒核盘菌菌株作为谷物生产和草坪管理的生物除草剂
  • 批准号:
    576545-2022
  • 财政年份:
    2022
  • 资助金额:
    $ 33.58万
  • 项目类别:
    Idea to Innovation
Investigating Host and Viral Factors for Improved Design of Future Live Attenuated Vaccines for IBV
研究宿主和病毒因素以改进未来 IBV 减毒活疫苗的设计
  • 批准号:
    BB/V016067/1
  • 财政年份:
    2022
  • 资助金额:
    $ 33.58万
  • 项目类别:
    Research Grant
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了